Jack Phillips - Apr 17, 2024 Form 4 Insider Report for Accelerate Diagnostics, Inc (AXDX)

Role
Chief Executive Officer, Director
Signature
/s/ David Patience, attorney-in-fact
Stock symbol
AXDX
Transactions as of
Apr 17, 2024
Transactions value $
-$20,853
Form type
4
Date filed
4/18/2024, 04:10 PM
Previous filing
Apr 16, 2024
Next filing
May 30, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXDX Common Stock Options Exercise $0 +59.9K +46.2% $0.00 190K Apr 17, 2024 Direct F1
transaction AXDX Common Stock Sale -$20.9K -26.7K -14.1% $0.78 163K Apr 17, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXDX Employee Restricted Stock Units Options Exercise $0 -59.9K -100% $0.00* 0 Apr 17, 2024 Common Stock 59.9K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 On March 5, 2024, the reporting person was granted a total of 119,856 restricted stock units ("RSUs"), of which 50% vest on April 12, 2024 and the remaining 50% vest on April 17, 2024. Each RSU represents a contingent right to receive one share of the issuer's common stock upon vesting.
F2 The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.